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Predictors of Epstein-Barr virus serostatus in
young people in England
Joanne R. Winter1* , Graham S. Taylor2†, Olivia G. Thomas2, Charlotte Jackson1,3, Joanna E. A. Lewis4† and
Helen R. Stagg1,5*
Abstract
Background: Epstein-Barr virus (EBV) is an important human pathogen which causes lifelong infection of > 90%
people globally and is linked to infectious mononucleosis (arising from infection in the later teenage years) and
several types of cancer. Vaccines against EBV are in development. In order to determine the most cost-effective
public health strategy for vaccine deployment, setting-specific data on the age at EBV acquisition and risk factors
for early infection are required. Such data are also important to inform mathematical models of EBV transmission
that can determine the required target product profile of vaccine characteristics. We thus aimed to examine risk
factors for EBV infection in young people in England, in order to improve our understanding of EBV epidemiology
and guide future vaccination strategies.
Methods: The Health Survey for England (HSE) is an annual, cross-sectional representative survey of households in
England during which data are collected via questionnaires and blood samples. We randomly selected individuals
who participated in the HSE 2002, aiming for 25 participants of each sex in each single year age group from 11 to
24 years. Stored samples were tested for EBV and cytomegalovirus (CMV) antibodies. We undertook descriptive and
regression analyses of EBV seroprevalence and risk factors for infection.
Results: Demographic data and serostatus were available for 732 individuals. EBV seroprevalence was strongly
associated with age, increasing from 60.4% in 11–14 year olds throughout adolescence (68.6% in 15–18 year olds)
and stabilising by early adulthood (93.0% in those aged 22–24 years). In univariable and multivariable logistic
regression models, ethnicity was associated with serostatus (adjusted odds ratio for seropositivity among individuals
of other ethnicity versus white individuals 2.33 [95% confidence interval 1.13–4.78]). Smoking was less strongly
associated with EBV seropositivity.
Conclusions: By the age of 11 years, EBV infection is present in over half the population, although age is not the
only factor associated with serostatus. Knowledge of the distribution of infection in the UK population is critical for
determining future vaccination policies, e.g. comparing general versus selectively targeted vaccination strategies.
Keywords: Epstein-Barr virus, Serostatus, Infectious mononucleosis, Cancer, Transmission, Risk factors
Background
Epstein-Barr Virus (EBV) is a herpesvirus that infects
90–95% of humans, causing lifelong infection [1, 2]. EBV
infection during childhood is generally asymptomatic,
however acquisition of EBV during adolescence or early
adulthood often causes infectious mononucleosis (IM),
[3] which can cause substantial morbidity during
important educational periods in adolescents and young
adults [4, 5]. EBV is associated with 1% of global cancers,
particularly Hodgkin’s lymphoma, Burkitt’s lymphoma,
nasopharyngeal cancer and gastric cancer [6].
EBV infection is not currently treatable nor prevent-
able by vaccination; however, vaccine candidates are in
development. In phase II trials, a first-generation vaccine
administered to healthy seronegative volunteers aged
16–25 years demonstrated protection against IM but not
EBV infection [7]. Second-generation vaccines elicited
higher levels of antibody responses in animal models, [8]
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and first-in-human trials are likely to begin soon. Math-
ematical modelling of different vaccination strategies is
essential to determine the effectiveness and cost-
effectiveness of different vaccination strategies for redu-
cing rates of EBV infection, IM, and EBV-associated can-
cers, taking into account factors such as vaccine efficacy,
duration of protection and differing outcomes according
to age at infection.
A greater understanding of EBV epidemiology, includ-
ing the dynamics of EBV infection in different sub-
populations, is necessary for the development of such
models. EBV seroprevalence increases with age; 90–95%
of people globally are infected by age 25, whilst 5–10%
remain seronegative throughout life [9]. The best public
health strategy for the deployment of an infection-
preventing vaccine may vary between settings; infection
appears to occur at younger ages in resource-limited
countries and thus children will need to be vaccinated
early [10–12]. However, if the duration of vaccine-
induced protection is not lengthy, vaccinated individuals
may become susceptible to natural infection at an age
where the consequences of infection are more severe, for
example leading to IM or cancer [13].
Additionally, sub-optimal vaccine coverage even of a
vaccine with a long duration of protection will lead to a
higher age at infection amongst those who remain un-
vaccinated. In such situations it may be better to delay
vaccination until the pre-teenage years, targeting individ-
uals who remain EBV seronegative. Alternatively, a vac-
cine protecting against IM and EBV-associated diseases
(such as certain cancers) could be administered to older
children as they approach adolescence, which may be ef-
fective even with a shorter duration of protection. After the
licensing of vaccine candidates, strategic discussions will
need to take place nationally and be informed by accurate
national data on the epidemiology of EBV infection.
In the United Kingdom, EBV seroprevalence increases
rapidly in very young children, reaching 21 and 51% by
the age of two years in children of white and Pakistani
ethnicity, respectively [14]. Another study showed that
EBV seroprevalence then remained relatively constant, at
around 55%, between the ages of five and 11 years [15].
EBV seroprevalence was estimated at 75% in university
students at 19 years and 92% by the age of 22 years [16].
We recently published summary data on the seropreva-
lence of EBV in adolescents in England [13]; however, to
date no study has investigated factors associated with
seropositivity that could inform a targeted vaccination
strategy.
Our aim was to investigate the sociodemographic and
lifestyle factors, particularly age, associated with EBV
serostatus in children and young adults in England, and
to discuss the implications of our findings for future
EBV vaccination policy.
Methods
Study population
The Health Survey for England (HSE) is an annual,
cross-sectional, representative survey of households in
England. Its methods are described in detail elsewhere
[17]. For this study, and in order to parameterise a
model of EBV transmission, [13] we randomly selected
individuals who participated in the 2002 HSE; 2002 was
the most recent year in which survey participants gave
consent for future studies to test their blood samples for
blood-borne viruses. Our aim was to include 25 partici-
pants of each sex in each single year age group from 11
to 24 years, in order to fill a gap in the literature and
capture the years at which infection is most likely to
have clinical consequences. The participant IDs were se-
lected randomly by the HSE, however it was not possible
at the time of sampling to determine whether the
samples had already been used. As a result, more than
25 IDs were selected for each age-sex group to ensure
there were sufficient samples for our analysis, and there-
fore there are not exactly 25 samples in each group
(Additional file 1: Table S1).
Measuring seroprevalence of Epstein-Barr virus and
cytomegalovirus infection
Stored blood serum samples collected between January
2002 and March 2003 were obtained from the HSE.
Samples were posted to the laboratory within two days,
where they were centrifuged, and the remaining serum
was frozen and stored at − 40°c until they were analysed,
which was completed in September 2017 [18].
EBV virus capsid antigen (VCA)-specific IgG and
CMV-specific IgG were detected in serum samples using
commercial ELISA kits obtained from EUROIMMUN,
Germany (EI2791–9601-G, EI2570-9601G). Assays were
performed according to manufacturer’s instructions and
serum antibody concentrations were calculated using a
standard curve. Data on the performance of the assays
are detailed in Additional file 1: Table S2. Results were
presented in relative units (RU/mL); <16RU/mL samples
were considered negative, ≤16 to <22RU/mL borderline
and ≥ 22RU/mL positive. Borderline results from the EBV
VCA IgG ELISA were subsequently subjected to re-
analysis with an EBV immunoblot assay (EUROIMMUN,
Germany, DY2790G) which revealed all borderline serum
samples (n = 5) had reactivity to alternative EBV antigens;
they were therefore considered seropositive.
Statistical analysis
Data were analysed in Stata version 15.0. We weighted
our sample, using the svy commands in Stata, to be
representative of the English population in 2002 with re-
spect to age and sex, utilising data from the Office for
National Statistics [19]. All stated percentages are
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weighted. Descriptive analyses of the study population
were undertaken. ArcMap 10.3.1 was used to create a
map of EBV seroprevalence by English Government Of-
fice Region [20].
To investigate factors associated with being seroposi-
tive for EBV, we undertook logistic regression modelling.
A causal inference framework was used to determine a
priori factors to be included in multivariable models,
from the available data collected in the HSE. We built
two multivariable regression models.
A ‘whole-population’ model, which included our entire
study population, examined the following factors: age,
sex, ethnicity (categorised as ‘white’ or ‘other’ due to
small numbers of non-white participants), body mass
index (BMI; categorised as ‘underweight’ [BMI < 20],
‘healthy weight’ [20-<25], ‘overweight’ [25-<30]or ‘obese’
[≥30]), region of England and CMV serostatus.
A second ‘adults-only’ model was restricted to individ-
uals aged ≥16 years, and additionally included factors for
which data was only available for adults; smoking status
(never smoked, current smoker, smoked in past) and
occupational category from the National Statistics Socio-
economic classification (NS-SEC) [21]. The NS-SEC
categorises occupations into higher managerial and
professional roles (involving strategy/supervision), inter-
mediate occupations (typically clerical, sales, service or
technical positions which do not involve general planning
or supervision), routine and manual occupations (involv-
ing basic labour), never worked or long-term unemployed,
and other. We excluded individuals missing data on one
or more variables.
Planned sensitivity analyses investigated the impact of
excluding CMV serostatus as a predictor of EBV serosta-
tus, and the impact of classifying the originally indeter-
minate serological results as seronegative rather than
seropositive.
Ethical approval
This study was approved by the University College
London Research Ethics Committee (5683/002). The
HSE obtained informed written consent for blood sam-
ples to be collected and stored for future analyses [17].
Results
Our study sample included 732 individuals aged 11–24 years,
of whom 547 (74.6%) were EBV-seropositive. The character-
istics of seropositive individuals are shown in Table 1.
EBV serostatus was associated with CMV serostatus;
72.6% of CMV-seronegative individuals were EBV seroposi-
tive compared to 80.9% CMV-seropositive individuals (χ2
test P = 0.04, Table 1). Considerable variation in EBV sero-
prevalence was observed by UK region (Fig. 1, Table 1).
EBV seropositivity increased with age, from 39.6% at 11–
14 years to 93.0% at 22–24 years (Fig. 2).
Factors associated with EBV seropositivity were largely
consistent between the univariable and multivariable
models (Table 2). Increasing age was associated with in-
creased EBV seroprevalence (adjusted odds ratio [aOR]
9.16 [95% confidence interval (CI) 4.38–19.14] for
people aged 22–24 years compared to those aged 11–14
years), as was non-white ethnicity (aOR 2.33 [1.13–
4.78]). CMV seropositivity was associated with EBV
seropositivity in the ‘adults-only’ multivariable model
(aOR 2.16 [1.05–4.43]) but not in the ‘whole population’
model (aOR 1.25 [0.79–1.98]).
Among adults, EBV seropositivity was higher among
those who currently smoked (aOR 4.29 [2.13–8.65]),
than those who had never smoked. There was no evi-
dence of associations between sex, BMI or occupational
category and EBV serostatus.
In sensitivity analyses, we firstly excluded CMV seros-
tatus as a predictor of EBV serostatus, and secondly we
classed indeterminate serology results (n = 5) as sero-
negative rather than seropositive. Both sensitivity ana-
lyses showed results consistent with our main analyses
(Additional file 1: Table S3, Table S4).
Discussion
The importance of EBV as a cancer-causing pathogen
has generated international interest in developing an
anti-infection vaccine [22]. The cost-effectiveness of dif-
ferent strategies to deploy such vaccines will vary from
setting to setting and is dependent on the epidemiology
of the infection. For example, EBV’s association with IM
means that vaccines that do not produce lifelong im-
munity may be better targeted towards subgroups which
are likely to acquire infection in adolescence. In this ob-
servational study of factors associated with EBV sero-
prevalence among young people in England in 2002, we
explored the distribution of seroprevalence by age and
the sources of additional variability. We found a substan-
tial increase in EBV seroprevalence with age among our
sample population, associations with ethnicity and smok-
ing, and a potential association with CMV seroprevalence.
A series of studies have demonstrated that EBV is gen-
erally acquired pre-adulthood, and that this varies be-
tween settings [12]. Our findings regarding smoking fit
with the prevailing narrative that there is an association
between EBV and socioeconomic status, rather than
smoking being an independent risk factor [12]. Unfortu-
nately, we did not have a good measure of socioeco-
nomic status in our analysis; the NS-SEC does not
account for familial socioeconomic status during child-
hood, which is probably more relevant to EBV sero-
prevalence than individual occupational status in young
adults, and we were unable to measure socioeconomic
status in children at all.
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Table 1 The number and weighted percentage of individuals seropositive for EBV in England in 2002
Whole cohort Adults only
EBV seropositive EBV seropositive
Variable Total number Number (weighted %) Total number Number (weighted %)
Total 732 547 (74.6) 472 389 (74.6)
Sex
Men 364 266 (72.5) 234 185 (78.8)
Women 368 281 (76.6) 238 204 (86.0)
CMV serostatus
CMV-seronegative 557 406 (72.6) 346 275 (79.6)
CMV-seropositive 175 141 (80.9) 126 114 (90.5)
Age last birthday
11–14 years 208 125 (60.4)
15–18 years† 212 145 (68.6) 160 112 (70.1)
19–21 years 156 132 (84.6) 156 132 (84.6)
22–24 years 156 145 (93.0) 156 145 (93.0)
Ethnic group
White 655 482 (73.4) 425 345 (81.2)
Other 77 65 (84.2) 47 44 (93.6)
BMI
Healthy weight 418 300 (71.6) 259 207 (79.8)
Underweight 60 47 (78.7) 60 47 (78.7)
Overweight 141 113 (79.6) 102 90 (88.3)
Obese 87 65 (74.8) 35 31 (89.1)
Missing 26 22 (84.6) 16 14 (87.5)
Region
East of England 78 50 (64.6) 52 39 (75.6)
North East 34 27 (79.8) 25 23 (91.8)
North West 130 98 (74.4) 80 66 (82.0)
Yorkshire and The Humber 82 70 (85.0) 58 51 (87.9)
East Midlands 74 57 (77.8) 48 39 (81.0)
West Midlands 70 46 (65.3) 33 24 (73.0)
London 63 50 (78.6) 42 37 (88.2)
South East 119 88 (73.4) 82 64 (78.2)
South West 82 61 (75.9) 52 46 (88.9)
Ever smokeda
Never smoked – – 186 137 (73.8)
Currently smoke – – 134 124 (92.5)
Smoked in past – – 147 124 (84.4)
Missing – – 5 4 (80.0)
Occupational categorya
Higher managerial and professional – – 83 71 (85.9)
Intermediate occupations – – 69 61 (88.3)
Routine and manual occupations – – 254 202 (79.6)
Never worked or long-term unemployed – – 11 10 (91.2)
Other – – 55 45 (81.4)
aAdults aged ≥16 years only (n = 472). †16–18 years for ‘adult-only’ model. Percentages account for the weighting of the sample to be representative of
the English population in 2002 with respect to age and sex. BMI: body mass index, CI confidence interval, CMV cytomegalovirus, EBV Epstein-Barr virus
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We found that EBV prevalence varied substantially be-
tween regions of the UK in univariable analyses and in
the whole-cohort model, but not in the adults-only
model, suggesting confounding between region and so-
cioeconomic status. There was also a strong association
between EBV seropositivity and ethnicities other than
white, in both univariable and multivariable models.
This may be the result of different mixing patterns (as
people of ethnic minorities are more likely to live in lar-
ger households), different feeding practices, or residual
confounding of socioeconomic status. CMV is another
herpesvirus which infects a high proportion of the popu-
lation from a young age, [23] and has also been associ-
ated with EBV in other settings [24, 25].
In England, EBV infects 55% of the population by the
age of 12 [15]; i.e. prior to adolescence, when the risk of
IM increases. Cost-effective deployment of a cheap,
infection-preventing, vaccine with a lifelong duration of
protection could thus likely involve targeting the early
years. However, future vaccines may produce a shorter
duration of immunity, potentially delaying infection and
resulting in an increasing incidence of IM (and IM-
associated cancers). This could be compounded by sub-
optimal vaccine coverage increasing the average age at
infection [26] and consequently potentially increasing
rates of IM – similarly to how sub-optimal coverage of
the MMR vaccine led to an increase in congenital ru-
bella syndrome in Greece [27, 28].
In such a scenario, targeted vaccine deployment to the
social groups who acquire infection later (when the like-
lihood of IM is higher) might be considered, possibly
with repeated dosing if required. Such targeting could be
Fig. 1 Weighted Epstein-Barr virus seroprevalence by English Government Office Region in 2002. Contains National Statistics data© Crown
copyright and database right [2011] Contains public sector information licensed under the Open Government Licence v3.0
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informed by the risk factors detected within this analysis,
and data such as those presented here should be consid-
ered in conjunction with the characteristics of the
vaccine available when determining what a vaccine pol-
icy should look like. If a vaccine was cheap and effective,
then universal coverage would be appropriate. If the dur-
ation of protection was short, it may be prudent to give
repeat doses of the vaccine to people who pick up the
infection at the youngest age, which is linked to ethnicity
and likely to socioeconomic status. The use of an expen-
sive vaccine could be stratified on the basis of who is
most likely to suffer EBV-related disease after infection,
which we have studied separately [29].
The limitations of our work include the age of the data
and the use of a cross-sectional study design, preventing
determination of the temporality of the correlation be-
tween EBV and CMV infection. In our analysis, EBV
seroprevalence was higher than CMV seroprevalence in
all age groups, and both increased with age. We found
that CMV was associated with EBV in univariable ana-
lyses, and in the adults-only model, but not in the
whole-cohort multivariable model. As both EBV and
CMV are associated with increasing age, particularly
during adolescence, we would not expect an association
between CMV and EBV to persist in the whole-cohort
multivariable model. It is possible that as the association
between age and EBV seroprevalence was less strong in
the adults-only multivariable model (as EBV seropreva-
lence starts to saturate as people reach adulthood), there
was enough of a residual effect that the association
between EBV and CMV could be detected. Unfortu-
nately, our sample size was not large enough to investi-
gate the interactions between EBV, CMV and age in
more detail. The association may result from shared
genetic, immunological and/or sociodemographic risk
factors, or one infection could increase susceptibility to
the other. Longitudinal studies with serial testing are ne-
cessary to explore this association, and additional risk
factors, in more detail.
We elected to measure IgG antibodies to the EBV VCA
protein and whole CMV virus, as these antibodies are
present in all infected individuals and persist for life. Al-
though we did not test for IgM antibodies, and cannot ex-
clude the possibility that some seronegative individuals
may have been recently infected, we note that VCA-
specific IgG and IgM antibodies usually appear contem-
poraneously [30] and therefore we would expect the
number of such individuals in our study to be low.
Conclusions
Knowledge of the distribution of EBV infection among
young population groups in England is critical for deter-
mining future vaccination policies, including the cost-
effectiveness of general versus selective approaches. Data
such as those presented here should be used together with
detailed information on vaccine characteristics, the impli-
cations of remaining EBV-uninfected for life, the ramifica-
tions of delayed infection, and the financial costs of IM
and EBV-associated cancers to inform such policies.
Fig. 2 Weighted seroprevalence of Epstein-Barr virus by age in England in 2002. CI: confidence interval, EBV- Epstein Barr Virus
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Table 2 Univariable and multivariable logistic regression models of factors associated with Epstein-Barr Virus seropositivity in
England in 2002
Univariable Multivariable (whole population) Multivariable (adults only)
OR (95% CI) P value aOR (95% CI) P value aOR (95% CI) P value
Sex
Male 1.00 1.00 1.00
Female 1.24 (0.87–1.75) 0.230 1.15 (0.79–1.67) 0.454 1.47 (0.86–2.53) 0.156
Age group (years)
11–14 1.00 1.00
15–18† 1.43 (0.97–2.11) 0.068 1.52 (1.01–2.30) 0.046 1.00
19–21 3.61 (2.13–6.13) < 0.001 3.76 (2.16–6.57) < 0.001 2.51 (1.31–4.82) 0.006
22–24 8.76 (4.30–17.83) < 0.001 9.16 (4.38–19.14) < 0.001 6.14 (2.64–14.27) < 0.001
Ethnicity
White 1.00 1.00 1.00
Other 1.93 (1.04–3.60) 0.038 2.33 (1.13–4.78) 0.021 4.26 (1.03–17.58) 0.045
BMI
Healthy weight 1.00 1.00 1.00
Underweight 1.46 (0.77–2.77) 0.243 1.13 (0.59–2.17) 0.718 1.13 (0.55–2.32) 0.731
Overweight 1.55 (0.97–2.49) 0.070 1.16 (0.69–1.95) 0.567 1.93 (0.88–4.24) 0.101
Obese 1.18 (0.65–2.13) 0.588 1.25 (0.67–2.33) 0.483 1.47 (0.45–4.77) 0.517
Region of UK
East of England 1.00 1.00 1.00
North East 2.16 (0.73–6.43) 0.166 2.46 (0.83–7.30) 0.105 4.78 (0.98–23.19) 0.052
North West 1.59 (0.82–3.10) 0.169 1.92 (0.94–3.90) 0.072 1.28 (0.55–2.99) 0.570
Yorkshire and The Humber 3.11 (1.41–6.84) 0.005 3.11 (1.39–6.98) 0.006 1.90 (0.73–4.95) 0.187
East Midlands 1.92 (0.87–4.20) 0.104 2.38 (1.06–5.33) 0.035 1.80 (0.67–4.87) 0.243
West Midlands 1.03 (0.50–2.10) 0.934 1.34 (0.63–2.86) 0.450 0.96 (0.28–3.26) 0.946
London 2.01 (0.90–4.52) 0.090 1.42 (0.61–3.29) 0.415 1.10 (0.37–3.24) 0.866
South East 1.51 (0.76–3.03) 0.242 1.84 (0.89–3.79) 0.099 1.27 (0.53–3.03) 0.589
South West 1.73 (0.87–3.43) 0.118 1.97 (0.93–4.17) 0.077 2.84 (0.87–9.24) 0.082
CMV serostatus
Seronegative 1.00 1.00 1.00
Seropositive 1.59 (1.06–2.39) 0.026 1.25 (0.79–1.98) 0.337 2.16 (1.05–4.43) 0.036
Smoking statusa
Never smoked 1.00 – – 1.00
Current smoker 4.40 (2.22–8.73) < 0.001 – – 4.29 (2.13–8.65) < 0.001
Smoked in past 1.92 (1.09–3.40) 0.025 – – 1.94 (0.99–3.81) 0.054
Occupational categorya
Higher managerial and professional 1.00 < 0.001 – – 1.00
Intermediate occupations 1.23 (0.43–3.53) 0.695 – – 1.54 (0.47–5.03) 0.469
Routine and manual occupations 0.64 (0.30–1.36) 0.245 – – 1.41 (0.62–3.22) 0.416
Never worked or long-term unemployed 1.70 (0.19–14.82) 0.631 – – 3.16 (0.22–45.85) 0.397
Other 0.72 (0.26–2.03) 0.533 – – 1.93 (0.56–6.69) 0.297
aAdults aged ≥16 years only (n = 472). †16–18 years for ‘adult-only’ model. Odds ratios account for the weighting of the sample to be representative of the English
population in 2002 with respect to age and sex. The ‘whole population’ multivariable model included age, sex, CMV serostatus, ethnicity, BMI and region of
England. The ‘adults only’ multivariable model included all variables shown in the table. aOR adjusted odds ratio, BMI body mass index, CI confidence interval,
CMV cytomegalovirus, OR unadjusted odds ratio
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